Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out
Journal of Clinical Oncology · 10.01.2025 · 43 (2) · 122-124
DOI: 10.1200/jco-24-01572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2025. Verfasst von Andreas Michael Schmitt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Melanoma, B7-H1 Antigen, Immune Checkpoint Inhibitors, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
- Department of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
- Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO.
ORCID-Profile: Andreas Michael Schmitt
Zitieren
APA
Schmitt, A. M., Larkin, J., & Patel, S. P. (2025). Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out. Journal of Clinical Oncology, 43(2), 122-124. https://doi.org/10.1200/jco-24-01572
Vancouver
Schmitt AM, Larkin J, Patel SP. Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out. Journal of Clinical Oncology. 2025;43(2):122-124. doi:10.1200/jco-24-01572
BibTeX
@article{Schmitt2025,
author = {Schmitt, Andreas Michael and Larkin, James and Patel, Sapna P},
title = {Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {2},
pages = {122--124},
doi = {10.1200/jco-24-01572}
}
EUVIMED